Drug-Induced Brugada Pattern: Common Culprits and Management
A drug-induced Brugada pattern is an electrocardiographic finding that can reveal latent sodium-channel dysfunction, result from direct toxic effects, or represent a transient Brugada phenocopy. The distinction matters because the ECG may resemble inherited Brugada syndrome while the patient’s immediate treatment, long-term risk, and need for an implantable cardioverter-defibrillator are different.
The characteristic abnormality is a type 1 pattern: a coved ST-segment elevation of at least 2 mm in the right precordial leads, followed by a negative T wave. It may appear spontaneously or after exposure to a sodium-channel blocker, fever, recreational substance, anesthetic, or psychotropic medication. The tracing can be intermittent, and a standard 12-lead ECG may miss it if leads V1 and V2 are not positioned in the second or third intercostal spaces.
Clinical assessment must therefore extend beyond the ECG. Symptoms, medication timing, fever, electrolyte balance, family history, structural heart disease, toxicology, and the circumstances surrounding syncope or cardiac arrest all contribute to risk assessment. A careful approach prevents both false reassurance and unnecessary labeling of a patient with a lifelong inherited disorder.
Recognizing The Electrocardiographic Pattern
The type 1 Brugada ECG is the only pattern considered diagnostic when the appropriate clinical context is present. It consists of a high takeoff, coved ST elevation in V1 or V2, and a subsequent inverted T wave. The morphology may be clearer with high right precordial leads, particularly when the initial ECG is nondiagnostic but suspicion remains high.
Type 2 and type 3 patterns, which show a saddleback configuration with less ST elevation, are suggestive rather than diagnostic. They can occur with right bundle branch block, lead misplacement, pectus anatomy, electrolyte abnormalities, ischemia, or other causes of right ventricular conduction delay. A medication-associated type 1 tracing should be interpreted alongside serial ECGs rather than treated as an isolated label.
Symptoms raise the clinical stakes. Unexplained nocturnal agonal breathing, arrhythmic syncope, polymorphic ventricular tachycardia, or ventricular fibrillation deserves urgent evaluation. Palpitations alone are less specific, since benign ectopy and supraventricular arrhythmias can produce similar complaints. In patients whose symptoms are dominated by persistent sinus tachycardia, the discussion of inappropriate sinus tachycardia criteria can help keep the differential diagnosis appropriately broad.
Medications And Exposures That Can Unmask It
The most important pharmacological triggers are potent sodium-channel blockers. Flecainide, propafenone, ajmaline, and procainamide can expose a type 1 pattern during diagnostic challenge or therapeutic use. Other class I agents, including pilsicainide where available, may have a similar effect. These drugs reduce the cardiac sodium current and can accentuate conduction abnormalities in the right ventricular outflow tract.
Toxic doses of tricyclic antidepressants, certain class I antiarrhythmics, cocaine, and some local anesthetics can produce marked sodium-channel blockade, QRS widening, hypotension, seizures, and ventricular arrhythmias. In these situations, the ECG may be part of a broader poisoning syndrome rather than evidence of inherited Brugada syndrome. Prompt toxicology treatment takes priority over formal electrophysiological classification.
Several non-cardiac drugs have been associated with Brugada ECG changes, including some psychotropic agents, anesthetic drugs, and antihistamines. Propofol has been reported in perioperative and infusion-related settings, although causality may be complicated by fever, autonomic shifts, critical illness, and concomitant medications. Alcohol excess, cocaine, and other recreational substances can also increase arrhythmic vulnerability through several mechanisms.
| Trigger or setting | Typical concern | Immediate clinical priority |
|---|---|---|
| Ajmaline, flecainide, procainamide, or propafenone | Sodium-channel blockade unmasking type 1 ECG | Stop exposure, repeat ECG, assess symptoms and rhythm |
| Tricyclic antidepressant overdose | Wide QRS, hypotension, seizures, ventricular arrhythmia | Toxicology support and intravenous sodium bicarbonate |
| Cocaine or stimulant exposure | Sodium-channel effects, ischemia, catecholamine excess | Stabilize rhythm and circulation; manage poisoning and ischemia |
| Fever or systemic infection | Increased expression of an underlying Brugada substrate | Prompt temperature control and infection treatment |
| Perioperative anesthetic exposure | Transient ECG change or malignant ventricular arrhythmia | Continuous monitoring, review anesthetic agents, correct triggers |
| Alcohol excess or withdrawal | Autonomic disturbance and increased arrhythmic risk | Supportive care, electrolyte correction, rhythm surveillance |
Separating Unmasking From A Brugada Phenocopy
A drug may unmask an underlying Brugada substrate without causing the condition itself. In this situation, the ECG normalizes after the drug is cleared, but the patient may still carry an inherited susceptibility. A phenocopy, by contrast, is a Brugada-like ECG caused by another acute condition, such as myocardial ischemia, electrolyte derangement, mechanical compression, pulmonary embolism, or severe metabolic illness, without evidence of a primary Brugada syndrome.
The distinction cannot be made from one tracing. Clinicians should document the precise drug, dose, route, timing, renal and hepatic function, co-exposures, temperature, and ECG evolution. A normal ECG after recovery does not automatically exclude inherited disease, particularly when there has been ventricular fibrillation, unexplained syncope, or a family history of sudden death.
Provocation testing with ajmaline or flecainide belongs in a specialist setting and should not be performed during acute intoxication or unstable illness. Testing may be considered after recovery when the diagnosis remains uncertain, but its interpretation depends on pretest probability and the quality of the ECG. Genetic counseling and testing can be useful in selected patients, although a negative genetic result does not rule out Brugada syndrome.
Stabilizing The Acute Presentation
The first action is to discontinue the suspected medication or exposure and assess airway, breathing, circulation, mental status, and rhythm. Patients with a type 1 pattern plus syncope, ventricular ectopy, fever, intoxication, or significant conduction delay generally require monitored care. Serial ECGs, continuous telemetry, glucose, electrolytes, renal function, cardiac biomarkers when indicated, and targeted toxicology testing help identify reversible drivers.
Fever should be treated promptly with antipyretics and physical cooling when necessary. Potassium, magnesium, calcium, and acid-base abnormalities should be corrected carefully. In sodium-channel blocker poisoning, intravenous sodium bicarbonate is a standard toxicological therapy for clinically important QRS widening, hypotension, or ventricular dysrhythmia, with dosing and monitoring guided by local poison-control protocols.
Electrical cardioversion or defibrillation is required for unstable ventricular tachycardia or ventricular fibrillation. Recurrent ventricular fibrillation, sometimes called an electrical storm, may respond to isoproterenol under specialist supervision, particularly when vagal predominance is suspected. Quinidine can be considered for recurrent arrhythmia in selected patients, but it is not a substitute for treating fever, poisoning, ischemia, or electrolyte disturbance.
Assessing Long-Term Arrhythmic Risk
Once the acute trigger has resolved, the patient needs a structured electrophysiology review. The key questions include whether the ECG was spontaneous or drug-provoked, whether syncope was likely arrhythmic, whether sustained ventricular arrhythmia occurred, and whether structural heart disease or another diagnosis explains the presentation. A drug-provoked type 1 pattern without symptoms generally carries a different risk profile from spontaneous type 1 ECG with documented ventricular fibrillation.
An implantable cardioverter-defibrillator is usually considered for survivors of cardiac arrest or patients with documented sustained ventricular tachycardia when no reversible cause remains. It is not automatically indicated solely because a sodium-channel blocker produced a type 1 pattern. Device decisions should account for age, comorbidity, competing risks, arrhythmia mechanism, and the possibility that the ECG represented a reversible phenocopy.
Supraventricular arrhythmias can coexist with Brugada syndrome and may be the reason a patient first enters cardiac care. When evaluating an older patient with symptomatic tachycardia, evidence on SVT ablation outcomes can inform a separate treatment decision without confusing supraventricular symptoms with malignant ventricular risk.
Preventing Recurrence In Clinical Practice
Patients should receive a written medication review and clear fever instructions. They should tell clinicians and anesthetists about the Brugada pattern before receiving new prescriptions, procedural sedation, or antiarrhythmic therapy. Medication avoidance lists are useful, but they should be checked against current specialist and pharmacovigilance resources because evidence for individual drugs can change and risk often depends on dose and clinical context.
Risk reduction also includes avoiding excessive alcohol and recreational drugs, maintaining hydration during illness, and seeking urgent care for fainting, nocturnal agonal breathing, sustained palpitations, or seizures. Family members may need evaluation when the presentation suggests inherited Brugada syndrome, particularly after unexplained sudden death or ventricular fibrillation at a young age.
Practical Steps For Safer Management
A consistent workflow reduces missed triggers and inappropriate long-term interventions:
- Confirm the ECG morphology with standard and high right precordial leads, then repeat it after the suspected trigger has been removed.
- Record every prescription, over-the-counter product, recreational substance, anesthetic, and recent dose change.
- Treat fever, poisoning, ischemia, hypoxia, and electrolyte abnormalities as urgent reversible causes.
- Use continuous monitoring for symptomatic patients, marked QRS widening, ventricular ectopy, syncope, or a type 1 pattern during acute illness.
- Refer survivors of ventricular fibrillation, patients with unexplained arrhythmic syncope, and those with a concerning family history to an electrophysiology service.
A medication-associated ECG should be communicated clearly at discharge, including whether the diagnosis is confirmed Brugada syndrome, a suspected unmasking event, or a phenocopy under evaluation. This wording helps future clinicians avoid both inadvertent rechallenge and unnecessary restrictions.
Drug-induced Brugada pattern recognition is most valuable when it leads to rapid stabilization, accurate diagnosis, and proportionate prevention. Clinicians can use the Journal of Arrhythmia’s research and educational resources to follow developments in electrophysiology, toxicological arrhythmias, ablation, and device-based care, while individualized decisions remain grounded in specialist assessment and the patient’s complete clinical history.